Last reviewed · How we verify
HUMAN INSULIN (BIOSYNTHETIC)
Human insulin (biosynthetic) replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.
Human insulin (biosynthetic) replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (insulin-dependent).
At a glance
| Generic name | HUMAN INSULIN (BIOSYNTHETIC) |
|---|---|
| Also known as | HR1799 |
| Sponsor | Sanofi |
| Drug class | Insulin |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Biosynthetic human insulin is produced through recombinant DNA technology and mimics endogenous insulin by binding to insulin receptors on target tissues, facilitating glucose transport into muscle and adipose tissue, and promoting anabolic metabolism. It is used to maintain euglycemia in patients with type 1 diabetes and insulin-dependent type 2 diabetes where endogenous insulin production is insufficient or absent.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (insulin-dependent)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
- Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia (NA)
- Sirtuin-NAD Activator in Alzheimer's Disease (PHASE1, PHASE2)
- Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus (NA)
- Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes (NA)
- Nutritional Status and Therapy in DMD Patients (NA)
- Human Skeletal Muscle Response to 5 Days of Bedrest in Young Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HUMAN INSULIN (BIOSYNTHETIC) CI brief — competitive landscape report
- HUMAN INSULIN (BIOSYNTHETIC) updates RSS · CI watch RSS
- Sanofi portfolio CI